News
The day at a glance · 2 min read
Mood · Risk-On
+72
Sentiment, −100 to +100
Moderna Q1 Revenue
$389M+260%
Moderna Q1 EPS Loss
$3.40+12.4% vs consensus
Pfizer Yield
6.4%
Key driverEli Lilly's weight-loss drug franchise continues delivering blockbuster revenue, driving optimism across the pharmaceutical sector
Daily briefHealthcare· Money365.Market AI ·

Lilly's Weight-Loss Surge Powers Healthcare Momentum

Big Pharma advances as Eli Lilly delivers blockbuster obesity drug revenue while Moderna posts strong international vaccine sales growth

Big Pharma & Biotech

Bullish
LLYMRNAPFE
Eli Lilly ($LLY) announced positive developments for shareholders as its weight-loss drug portfolio continues delivering blockbuster revenue, with a new oral weight-loss pill expanding the pharmaceutical leader's already massive market opportunity. The company is among major corporations committing to $9 trillion in U.S. manufacturing investment. Meanwhile, Moderna ($MRNA) reported Q1 2026 results exceeding revenue expectations, with sales climbing 260% year-over-year to $389 million driven by strong international partnerships, though the company posted a GAAP loss of $3.40 per share that was 12.4% above analyst consensus.
Pfizer ($PFE) shares remain down 50% from their 2021 high, with the stock now offering a 6.4% dividend yield.

FDA & Regulation

Bullish
ABBV
AbbVie ($ABBV) announced that SKYRIZI (risankizumab), an IL-23 inhibitor, has been listed on Ontario and Alberta formularies for the treatment of moderately to severely active ulcerative colitis. The formulary listings follow the drug's positive regulatory reception in Canada, expanding access for patients with this inflammatory bowel condition. This represents a significant commercial milestone for AbbVie's immunology franchise in the Canadian market.

MedTech & Devices

Neutral

ISRG Share Price (Apr 21)

$451.29

ISRG Trailing P/E

59.16

ISRG Forward P/E

46.51
ISRGJNJ
Intuitive Surgical ($ISRG) is drawing analyst attention amid a competitive surgical robotics landscape, with shares trading at $451.29 as of April 21st. Market commentators note that both Johnson & Johnson ($JNJ) and Medtronic claim to have developed competitive robotic surgery platforms, raising concerns about potential market share pressure on the da Vinci system leader.
$ISRG shares trade at a trailing P/E of 59.16 and forward P/E of 46.51, reflecting premium valuations that may face scrutiny as competition intensifies in the surgical robotics space.

Company Developments

Neutral

Yacktman Portfolio Value

$7.5B

Yacktman Cash Position

11.5%
BMYJNJ
Bristol Myers Squibb ($BMY) launched a media campaign titled "Won't Lose" ahead of the FIFA World Cup 2026, highlighting the company's commitment to advancing patient breakthroughs. The campaign emphasizes BMS's relentless drive in pharmaceutical innovation. Separately, $BMY recently beat first-quarter earnings expectations, prompting positive analyst commentary on the company's performance. Investment activity continues across the sector, with Yacktman Asset Management's Q1 2026 portfolio rising to approximately $7.5 billion across 76 holdings with 11.5% cash, maintaining Canadian Natural Resources as its largest position at 10.75%.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy